Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.
Shonibare Z, Monavarian M, O'Connell K, Altomare D, Shelton A, Mehta S, Jaskula-Sztul R, Phaeton R, Starr MD, Whitaker R, Berchuck A, Nixon AB, Arend RC, Lee NY, Miller CR, Hempel N, Mythreye K. Shonibare Z, et al. Among authors: shelton a. Cell Rep. 2022 Jul 26;40(4):111066. doi: 10.1016/j.celrep.2022.111066. Cell Rep. 2022. PMID: 35905726 Free PMC article.
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
Rehman H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, Balasubramanya SAH, Shelton AK, Skinner KR, Ma AH, Rao T, Agarwal S, Eich ML, Robinson AD, Naik G, Manne U, Netto GJ, Miller CR, Pan CX, Sonpavde G, Varambally S, Ferguson JE 3rd. Rehman H, et al. JCI Insight. 2022 Aug 22;7(16):e155899. doi: 10.1172/jci.insight.155899. JCI Insight. 2022. PMID: 35852858 Free PMC article.
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.
Bajpai P, Agarwal S, Afaq F, Al Diffalha S, Chandrashekar DS, Kim HG, Shelton A, Miller CR, Singh SK, Singh R, Varambally S, Nagaraju GP, Manne A, Paluri R, Khushman M, Manne U. Bajpai P, et al. Among authors: shelton a. J Exp Clin Cancer Res. 2024 Jul 11;43(1):192. doi: 10.1186/s13046-024-03106-8. J Exp Clin Cancer Res. 2024. PMID: 38992681 Free PMC article.
Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby GN, Wang Y, Wang C, Gao Y, Anand JR, Shelton A, Satterlee AB, Mann B, Hsiao YC, Liu CW, Lu K, Hingtgen S, Wang J, Liu Z, Miller CR, Wu D, Vaziri C, Yang Y. Cheng X, et al. Among authors: shelton a. Nat Commun. 2024 Mar 4;15(1):1957. doi: 10.1038/s41467-024-45979-5. Nat Commun. 2024. PMID: 38438348 Free PMC article.
Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby G, Wang Y, Wang C, Gao Y, Shelton A, Satterlee AB, Mann BE, Hsiao YC, Liu CW, Liu K, Hingtgen S, Wang J, Liu Z, Miller R, Wu D, Vaziri C, Yang Y. Cheng X, et al. Among authors: shelton a. bioRxiv [Preprint]. 2023 Oct 19:2023.10.16.562506. doi: 10.1101/2023.10.16.562506. bioRxiv. 2023. Update in: Nat Commun. 2024 Mar 4;15(1):1957. doi: 10.1038/s41467-024-45979-5 PMID: 37905107 Free PMC article. Updated. Preprint.
Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby G, Wang Y, Wang C, Gao Y, Shelton A, Satterlee AB, Mann BE, Hsiao YC, Liu CW, Liu K, Hingtgen S, Wang J, Liu Z, Miller R, Wu D, Vaziri C, Yang Y. Cheng X, et al. Among authors: shelton a. Res Sq [Preprint]. 2023 Oct 16:rs.3.rs-2367368. doi: 10.21203/rs.3.rs-2367368/v1. Res Sq. 2023. Update in: Nat Commun. 2024 Mar 4;15(1):1957. doi: 10.1038/s41467-024-45979-5 PMID: 37886584 Free PMC article. Updated. Preprint.
436 results